Clinical trials: Glucose Tolerance
Impaired Glucose Tolerance, Insulin Resistance
Safety, Tolerability, PK, and PD of LIM-0705 in Subjects With Impaired Glucose Tolerance or Abnormal HOMA-IR
Preliminary research suggests that LIM-0705 improves insulin sensitivity with neutral effects on weight in obese and diabetic rodent models.
- Trial name
- NCT01364155
- Testing
- LIM-0705
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Limerick BioPharma
Impaired Glucose Tolerance, Abdominal Obesity
Pilot Study With GFT505 (80mg) in Patients Presenting With Impaired Glucose Tolerance and Abdominal Obesity.
The purpose of this study is to evaluate the efficacy of GFT505 80mg compared with placebo in improving Oral Glucose Tolerance Test (OGTT), in patients with impaired glucose tolerance and abdominal obesity, and to assess the…
- Trial name
- NCT01275469
- Testing
- GFT505 80mg
- Where
- 20 sites in France
- Volunteers
- 47 people
- Sponsor
- Genfit
Impaired Glucose Tolerance
Investigation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LIM-0705 in Male Subjects With Impaired Glucose Tolerance
LIM-0705 will gain results on the effects of LIM-0705 on Male Subjects with Impaired Glucose Tolerance
- Trial name
- LIM (NCT01093677)
- Testing
- LIM-0705
- Volunteers
- 30 people
- Sponsor
- Limerick BioPharma
Hypertension, Impaired Glucose Tolerance
Evaluation of Soluble Epoxide Hydrolase (s-EH) Inhibitor in Patients With Mild to Moderate Hypertension and Impaired Glucose Tolerance
The purpose of this study is to determine the safety and efficacy of AR9281, a novel s-EH enzyme inhibitor, in improving glucose metabolism and blood pressure in patients with impaired glucose tolerance and mild to moderate…
- Trial name
- NCT00847899
- Testing
- AR9281
- Where
- 30 sites in United States
- Volunteers
- 150 people
- Sponsor
- Arete Therapeutics